The Neural Analytics Lucid™ M1 transcranial Doppler Ultrasound System is indicated as an adjunct to the standard clinical practices for measuring and displaying cerebral blood flow velocity within the major conducting arteries and veins of the head and neck. Additionally, the Lucid™ M1 System measures the occurrence of transient emboli signals within the blood stream.
Technology topic
Pharmaceutical Technologies (PT)
The Pharmaceutical Technologies topic covers a wide range of technology areas to advance the discovery, early-stage development and characterization, formulation, delivery, and/or manufacture of novel drugs, moieties, compounds, products, processes, platforms or services that will improve the selection, quality, or price of pharmaceutical and biologic therapies.
The Pharmaceutical Technologies topic is not aimed at supporting or conducting clinical trials, clinical efficacy or safety studies, the development of pre-clinical or clinical-stage drug candidates or medical devices, or work performed primarily for regulatory purposes. Limited studies with human subjects may be acceptable to the extent that they are performed in support of feasibility, proof-of-concept studies of early-stage technologies and must follow NSF policies on research on human subjects. Proposals that request support for clinical studies will be deemed non-compliant with the SBIR/STTR solicitations and may be returned without review.
Sub-Topics
PT1. Drug Delivery Methods
PT2. Drug Discovery
PT3. Health in Underserved Communities
PT4. Pharmaceutical and Biologic Manufacturing
PT5. Therapeutic Molecules
PT6. Women’s Health
PT7. Other Pharmaceutical Technologies
Featured Companies
Detecting biological contaminants in water & pharmaceuticals
Spheryx, Inc. created a technology to monitor, count and characterize microscopic particles in a variety of fluids, such as water, chemicals, or even pharmaceuticals.
To learn more visit: https://spheryx.solutions/
A polymer material (blue) targets drug activation of doxorubicin (red) to tumors, minimizing toxicity because the drug is shielded while in the blood (green). Photo credit: Shasqi
New drug delivery technology for tumor treatment
Shasqi, a small business funded by the National Science Foundation, is developing a new way to deliver drugs to specific locations within the body to more effectively treat diseases such as cancer. The team, led by physician and chemist Dr. Jose M. Mejia Oneto, has created a targeting system that could enable effective therapy with lower doses of drugs and fewer harmful side effects.
The system works by first injecting a gel at the treatment site. The gel contains chemicals that combine with and activate an injected, attenuated form of a drug, such as a chemotherapeutic, to trigger its cancer-fighting effect only at the tumor or other targeted tissue. The experimental treatment has been successfully tested against tumors in mice, which experienced tumor shrinkage while maintaining healthier weights than mice receiving traditional chemotherapeutic treatments. Shasqi
Jose M. Mejia Oneto, founder and CEO of Shasqi. Photo credit: Shasqi